For most immune-mediated diseases, the main determinant of patient well-being is not the diagnosis itself but instead the course that the disease takes over time (prognosis) [1] [2] [3] . Prognosis may vary substantially between patients for reasons that are poorly understood. Familial studies support a genetic contribution to prognosis [4] [5] [6] , but little evidence has been found for a proposed association between prognosis and the burden of susceptibility variants [7] [8] [9] [10] [11] [12] [13] . To better characterize how genetic variation influences disease prognosis, we performed a withincases genome-wide association study in two cohorts of patients with Crohn's disease. We identified four genome-wide significant loci, none of which showed any association with disease susceptibility. Conversely, the aggregated effect of all 170 disease susceptibility loci was not associated with disease prognosis. Together, these data suggest that the genetic contribution to prognosis in Crohn's disease is largely independent of the contribution to disease susceptibility and point to a biology of prognosis that could provide new therapeutic opportunities.
Despite the success of genome-wide association studies (GWAS) in immune-mediated disease, the genetic contribution to aspects of disease other than susceptibility remains largely unstudied. One of the most important aspects from a clinical perspective is prognosis. For example, in Crohn's disease, a relapsing-remitting form of inflammatory bowel disease (IBD), some patients experience frequent relapses and require treatment with increasingly potent immunosuppressants and/or surgery, whereas others achieve prolonged remission without any additional therapy 1 . Such variability in prognosis occurs in most immune-mediated diseases 2, 3 and can make the difference between an excellent long-term outcome or progressive disability and death [1] [2] [3] .
What determines prognosis is poorly understood, although a genetic contribution has been proposed on the basis of similar patterns of disease behavior often being observed within families [4] [5] [6] . Thus far, investigation into the genetics of prognosis has largely focused on susceptibility variants [7] [8] [9] because of the hypothesis that disease development and prognosis have a common genetic architecture 14 . Attempts to prove this hypothesis, however, have largely failed to demonstrate replicable associations [10] [11] [12] [13] . For example, although NOD2 variants were initially associated with increased need for surgery in Crohn's disease 15 , this finding has since been attributed to their association with ileal disease 10, 11, 16 (the distribution of Crohn's disease that is more commonly treated with surgery, as the procedure carries a lower rate of morbidity). A subphenotype analysis of IBD recently showed that susceptibility variants only explain a minority of phenotypic variance (mainly with respect to disease location) and that, after conditioning on disease location and age at diagnosis, there is little or no association with disease behavior 16 .
An alternative possibility is that the genetic contribution to prognosis might be distinct from that which confers disease susceptibility. The idea of a separate biology for prognosis would fit with the observation that CD8 T cell exhaustion correlates with outcome, but not diagnosis, in multiple immune-mediated diseases 17 and the identification of a SNP in FOXO3 that associates with prognosis, but not susceptibility, in several diseases-including Crohn's disease 18 .
To better understand the genetic contribution to prognosis in Crohn's disease, we performed a within-cases GWAS in two Crohn's disease cohorts and performed meta-analysis of the results. To do this, we first identified patients at opposite ends of the prognostic spectrum for comparison. This approach enriches for alleles influencing prognosis and makes associated variants easier to detect because the odds ratios between extreme groups are higher than in the total sample 19 .
Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease Poor-prognosis Crohn's disease was defined as frequently flaring, treatment-refractory disease that required consecutive treatment with ≥2 immunomodulators, ≥2 abdominal surgeries, or a combination of the two 18 . Good-prognosis Crohn's disease was defined as indolent disease that had not required treatment with immunomodulators or surgery despite ≥4 years follow-up 18 (median, 12 years). These definitions were applied to two cohorts of Crohn's disease cases: the first from a previous GWAS 20 (669 poor-prognosis cases, 389 good-prognosis cases) and the second comprising cases who were genotyped using UK Biobank Axiom arrays (1,093 poor-prognosis cases, 583 goodprognosis cases). Altogether, 19.2% of cases had good-prognosis Crohn's disease and 32.2% had poor-prognosis Crohn's disease. Patients with an intermediate phenotype were excluded (n = 2,794; 48.6%). At genome-wide significance (P < 5 × 10 −8 ), the combined data set had ≥80% power to detect variants (minor allele frequency (MAF) >20%) with odds ratios ≥1.33. l e t t e r S l e t t e r S Standard quality control checks for SNPs and samples were performed prior to imputation against the UK10K reference panel 21 (Online Methods). Following imputation quality control (Online Methods and Supplementary Table 1), we tested 7.0 million and 7.5 million SNPs for association in cohorts 1 and 2, respectively, and performed meta-analysis of the results. Cluster plots for associated SNPs were inspected to confirm genotyping, and if the SNPs were imputed they were then genotyped to confirm imputation (Online Methods and Supplementary Table 1 ). The genomic control inflation factor (λ GC ) was 1.023 in the combined analysis ( Supplementary  Fig. 1 ).
Four loci passed genome-wide significance. These association signals were located in FOXO3, XACT, a region upstream of IGFBP1, and the major histocompatibility (MHC) region (Fig. 1a, Table 1 , and Supplementary Table 2 ). The associated FOXO3 haplotype, which was previously identified in a candidate gene study using the same definitions 18 , regulates FOXO3 expression and controls a TGF-β1-dependent pathway that limits inflammatory responses in monocytes 18 . By genotyping or imputing 115 of 118 SNPs at this locus, we mapped the peak association signal to an intronic region that contains enhancer marks (H3K4me1, H3K27ac, p300 binding) and transcription factor binding sites, consistent with the reported expression quantitative trait locus (eQTL) 18 (Fig. 1b and  Supplementary Fig. 2 ).
The second association signal was located within XACT (Fig. 1c) , a gene that encodes a long noncoding RNA that is only expressed from the active X chromosome 22 and that resides over 630 kb from the nearest protein-coding gene. This association was detectable in both males and females (Supplementary Table 2 ). Although XACT has been studied in pluripotent stem cells 22 , its function in differentiated cells is unknown. Given the association with Crohn's disease prognosis, however, it was striking that, across multiple human tissues, XACT was most highly expressed within the intestine (Supplementary Fig. 3) .
The third association signal was located immediately upstream of IGFBP1 in a region that also contains IGFBP3 (Fig. 1d) . The associated SNP at this locus (rs75764599[G>A], g.45899250G>A, hg19) was conspicuous for its lack of linkage disequilibrium (LD) with local SNPs and had to be directly genotyped in cohort 1. Although long-range LD enabled imputation in cohort 2 (INFO score = 0.82), we genotyped the SNP in this cohort as well to confirm the association (Supplementary Table 1 ). This relative lack of LD is sometimes observed at low-frequency SNPs, and it implies that rs75764599[G>A] is likely to be the causal variant. IGFBP-1 and IGFBP-3 belong to a family of proteins that bind to and prolong the half-lives of insulinlike growth factors I and II; these are proteins involved in processes including immunity and longevity 23 . The IGFBP1 locus has also been associated with antibodies to citrullinated peptides in rheumatoid arthritis 24 . In rheumatoid arthritis, the presence of these antibodies predicts poor prognosis 24 , suggesting that this region might influence prognosis in Crohn's disease and rheumatoid arthritis through a common pathway, as was shown for FOXO3 (ref. 18 ).
The final association signal was located in the MHC region and stretched from HLA-B to the HLA-DR genes (Fig. 1e) . Despite the breadth of this signal, conditioning on the lead SNP resulted in the identification only one associated haplotype (Fig. 2a) . To assess whether specific HLA alleles were responsible for this genetic association, we imputed classical four-digit HLA alleles and detected associations at multiple class I and class II genes. Notably, all of the associated alleles belonged to a single multigene haplotype, 'ancestral MHC 8.1' (AH8.1; Fig. 2b) . Indeed, the strength of each allelic association correlated with how specific that allele was to AH8.1 ( Supplementary Fig. 4 ). To clarify the contribution of AH8.1 to the genetic signal, we performed cross-conditioning to assess the residual associations when the SNP analysis was conditioned on the lead AH8.1 allele (HLA-B*08:01) and vice versa. In both directions, cross-conditioning abrogated any association, demonstrating that inheritance of AH8.1 was the major contributor to the genetic signal ( Fig. 2c and Supplementary Table 3) . Carriers of this haplotype are known to exhibit impaired responses to vaccination 25 and defects in T cell activation 26, 27 , which are consistent with HLA-specific differences in antigen presentation. The increased frequency of this haplotype in good-prognosis Crohn's disease is therefore consistent with the notion that differential T cell activation influences prognosis in immune-mediated disease 17 . Interestingly, no association was observed at HLA-DRB1*01:03, the HLA allele that has by far the strongest association with Crohn's disease susceptibility of any HLA allele or SNP 28 ( Fig. 2b and Supplementary Table 3) . Similarly, the prognosis-associated MHC SNPs did not overlap with known disease susceptibility SNPs (Supplementary Fig. 5 ).
We next investigated whether these associations were dependent on the criteria used to define prognosis. We found that the results could not be attributed to differences in disease location (Supplementary Table  4 ) or follow-up (Supplementary Table 5 ) and that three of the four associations remained genome-wide significant, even if another definition of poor prognosis was used: abdominal surgery within 2 years of diagnosis 29 (Supplementary Table 6 ). These associations are therefore likely to be involved in the biology that determines prognosis in Crohn's disease, as was shown for FOXO3 (ref. 18) . To further explore this underlying biology, we examined whether genes tagged by an extended list of prognosis-associated SNPs (meta P < 1 × 10 −5 ) were enriched within specific biological pathways (Online Methods). Strong enrichment was observed for pathways that regulate innate and adaptive immune responses and responses to microorganisms (Fig. 3a) . Similar results were obtained if SNPs within the extended MHC region were removed (Supplementary Table 7 ). To identify the cell types involved, we examined whether there was tissue-specific enrichment using an expression atlas of primary human cells 30 . Strong enrichment was observed in macrophages, 
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Crohn's disease prognosis SNPs are shown that met genome-wide significance (P < 5 × 10 −8 ) in the combined analysis and nominal significance (P < 0.05) in both individual cohorts. The odds ratio is presented with respect to the minor allele and the risk of poor-prognosis Crohn's disease. Allele frequency data are presented for the good-prognosis Crohn's disease cohort. Chr., chromosome; RAF, risk allele frequency; ind., indolent (good-prognosis) Crohn's disease; OR, odds ratio; 95% CI, 95% confidence interval for the odds ratio. Fig. 6 ). Interestingly, the four prognosis-associated haplotypes have not been associated with Crohn's disease susceptibility in any GWAS, including a recent meta-analysis 31 (Supplementary Table 9 ). l e t t e r S Accordingly, if they were to influence disease susceptibility, their effect size would likely be negligible. Conversely, after stratifying for disease location-to control for associations of some loci (e.g., NOD2) with distributions of Crohn's disease that could affect assessments of clinical outcome 10, 11, 16 -none of the 170 susceptibility variants 31, 32 were associated with prognosis, even if more relaxed statistical thresholds were used (Online Methods and Supplementary Table 10 ).
There was also no correlation between the power to detect effects at these SNPs and the observed P values; this is consistent with the hypothesis that susceptibility variants are not individually associated with prognosis ( Supplementary Fig. 7) . Similarly, genome-wide LD score regression confirmed that there was no significant overlap between the genetic bases of susceptibility and prognosis in Crohn's disease when disease location was taken into account (genetic correlation = −0.51, standard error = 0.33; P = 0.121).
To determine whether susceptibility variants might collectively influence prognosis, we calculated genetic risk scores for each patient, but again no significant differences were observed between the good-and poor-prognosis subgroups (Fig. 4) . This result did not change when an extended list of Crohn's disease-associated SNPs was used 33 that was based on susceptibility variants with meta P < 1 × 10 −4 ( Supplementary Fig. 8 ). Together, these data suggest that susceptibility alleles do not meaningfully contribute to prognosis in Crohn's disease, although a weak effect cannot be excluded because of the power of this analysis. If such an effect were to occur, however, it would be trivial in comparison to the effects of non-susceptibility loci that are associated with prognosis.
Collectively, these data establish that the main genetic contribution to prognosis comes from loci that are distinct from those that drive disease susceptibility and demonstrate that disease initiation Figure 3 Pathway analysis implicates regulation of immune responses and mononuclear phagocytes in Crohn's disease prognosis. (a) Horizontal bar plot of -log 10 (P values) for the top 40 most enriched pathways in an analysis of 29 LD-pruned prognosis-associated SNPs (meta P < 1 × 10 −5 ) across 1,751 pathways annotated by Gene Ontology (GO). Asterisked pathways (highlighted in red) passed a Bonferroni-corrected significance threshold (P < 2.9 × 10 −5 ). (b) Bar plot of -log 10 (P values) for 155 specific cell types and conditions. Significant enrichment was observed in 'monocyte-derived macrophages stimulated by M-CSF' and 'monocyte-derived macrophages stimulated by M-CSF and interferon-γ'. Other non-immune cell types included neural, skin, lung, liver, stem, smooth muscle, stromal, bone marrow progenitor, endothelial, and epithelial cells. The dashed line represents the Bonferroni-corrected significance threshold. Analyses were performed using SNPsea.
l e t t e r S
is not only temporally distinct from active symptomatic disease, but also appears to be governed by separate genetics. This provides a starting point for better understanding the biology that determines prognosis in Crohn's disease and could lead to new and potentially improved opportunities for therapeutic intervention. This also has implications for 'personalized medicine' , although any genetic classifier would need to work in unselected Crohn's disease cases (in whom the odds ratios at prognosis-associated variants will be smaller than those that were observed here). More generally, this work illustrates the value of reanalyzing existing GWAS data using carefully selected subphenotypes. Indeed, providing sufficiently detailed clinical data are available, this approach should be broadly applicable and could yield important new insights into multiple diseases. Weights were based on β coefficients calculated from the odds ratios reported in Liu et al. 31 for 170 Crohn's disease susceptibility SNPs. n = 2,413 (779 good-prognosis cases, 1,634 poor-prognosis cases). (b) Distribution of unweighted susceptibility allele counts between goodprognosis and poor-prognosis Crohn's disease subgroups. Statistical significance was assessed using an unpaired two-tailed Student's t test and was stratified for disease location. Whiskers extend to maximum and minimum values.
oNLINe MeThods Study subjects. Following ethical approval by Cambridge MREC (reference 03/5/12) and Mater Health Services, Christchurch Hospital, two cohorts of unrelated Crohn's disease cases of northern European descent were considered (cohort 1, n = 1,748; cohort 2, n = 3,999). These cases were enrolled by the UK IBD Genetics Consortium (n = 5,521) and the University of Otago, New Zealand (n = 226), and all provided written informed consent. All cases were treated using a 'step-up' treatment strategy in which immunosuppression is incrementally escalated, but only in response to persistently flaring disease. Subgroups of patients with a poor prognosis or a good prognosis were identified using phenotype data. Poor-prognosis Crohn's disease was defined as disease that had required ≥2 immunomodulators or ≥2 abdominal surgeries, or a combination of these (for example, 1 immunomodulator and 1 intestinal resection). Following quality control, 1,762 cases met this definition (cohort 1, n = 669; cohort 2, n = 1,093). Good-prognosis Crohn's disease was defined as disease of ≥4 years in duration that had not required immunomodulators or intestinal resections (median of 12 years). Following quality control, 972 cases met this definition (cohort 1, n = 389; cohort 2, n = 583). Patients who did not meet either set of criteria, or who had only required additional immunomodulators or surgery because of drug intolerance or complications of earlier surgery, respectively, were excluded.
Genotyping. Samples in cohort 1 were genotyped as part of an earlier GWAS 20 . For this cohort, normalized intensity data were downloaded from the European Genome-phenome Archive (EGA). Samples in cohort 2 were genotyped using the UK Axiom Biobank array (Affymetrix). Twenty-seven SNPs (including rs75764599 [G>A] ; IGFBP1 locus) demonstrated modest evidence of association in cohort 2 (P < 5 × 10 −5 ) but could not be imputed in cohort 1. These markers were directly genotyped in cohort 1 using TaqMan SNP genotyping assays. Imputed low-frequency SNPs (MAF = 1-5%) that showed evidence of association were also directly genotyped to confirm imputation. Data processing. Cohort 1. Marker quality control. Markers that failed quality control checks in the original GWAS 20 were excluded. Genotypes were called from the normalized intensity data using CHIAMO. SNPs with overall missingness >0.05 or differential missingness >0.02 were excluded. Because there were no healthy controls in this study (in whom deviation from HardyWeinberg equilibrium is usually assessed 34 ), only SNPs with marked deviation from Hardy-Weinberg equilibrium were excluded (P < 1 × 10 −10 ).
Sample quality control. Samples that failed quality control criteria in the original study 20 were excluded. The reported sex of each case was checked against genotype-inferred sex using PLINK 35 . Samples with sex mismatch were excluded. Samples with a genotype missingness rate >0.05 or heterozygosity rate greater than 2 s.d. from the mean were also excluded 34 . To identify related samples, 119,811 LD-independent SNPs were selected and pairwise identity by descent was estimated using PLINK 35 (pi-hat threshold of 0.1875). For any related samples, one case was randomly selected and kept and the other(s) were excluded.
Geographical outliers. A pruned version of the data set, containing 56,919 LD-independent SNPs, was merged with the 1000 Genomes Project data set 36 . Principal-component analysis (PCA) was used to identify and exclude geographical outliers.
In total, 62 samples in cohort 1 failed quality control. Cohort 2. In addition to standard pre-genome-wide-association quality control measures, additional quality controls specific to the Axiom genotyping array were recommended by the manufacturers (Affymetrix). These were performed prior to standard quality control.
Axiom-specific sample quality control. Genotyping arrays were batched by processing date and analyzed separately according to the manufacturer's instructions. The dish quality control (DQC) metric (the recommended quality metric for Axiom genotyping arrays) was computed for each sample. Samples with DQC < 0.82 were excluded, according to the manufacturer's recommendations. Samples with a preliminary call rate ≤ 97% at a set of 20,000 validated autosomal markers were also excluded. Plates with an average preliminary call rate of passing samples < 98.5% were excluded, according to the manufacturer's recommendations.
Axiom-specific marker quality control. Genotypes were called separately for each batch using the 'apt-probeset-genotype' utility with default parameters.
Quality control metrics for each marker were computed using the 'Ps_Metrics' function in 'SNPolisher' in R and used to classify markers on the basis of the quality of the signal. Markers classified in categories 'PolyHighRes' , 'NoMinorHom' and 'MonoHighRes' were selected for further analysis. 500 probe sets from each selected category were randomly selected and inspected to confirm the classification.
Standard sample and marker quality control. In addition to the Axiomspecific quality control measures, standard pre-genome-wide-association quality control steps were applied as described for cohort 1.
In total, 71 samples in cohort 2 failed quality control.
Genotype imputation. Genotype imputation was performed using IMPUTE2 (ref. 37) after estimating haplotypes with SHAPEIT2 (ref. 38 ) and the UK10K reference panel 21 . Default SHAPEIT2 parameters were modified (-states 500 -burn 10 -prune 10 -main 50) to improve accuracy by increasing the number of conditioning states 39 . Samples from each cohort were prephased and imputed in a single batch, to avoid batch effects attributable to the imputation process. To make computation feasible, the data set was divided into ~3,000 overlapping 1-Mb regions. IMPUTE2 was used with option -buffer 2000 to leverage on a genomic window of 5 Mb (comprising the 1-Mb analyzed region plus 2-Mb buffer regions on either side). Results were controlled and reassembled in R. Phasing and imputation of the X chromosome were performed using the -chrX flag, and the sex of each sample was provided. Imputed variants with MAF < 1% and/or INFO score < 0.8 were excluded. To estimate imputation accuracy, imputed genotype calls at 99,124 SNPs were compared with direct genotyping data in 880 cases (Illumina Immunochip 32 ). Mean concordance was 99.3% (Supplementary Table 1 ).
Power calculations. Power calculations were performed using the GPC function in the GeneticsDesign package in R. The prevalence of poor-prognosis Crohn's disease was calculated using the total number of poor-prognosis cases (prior to quality control) as a proportion of all of the cases considered (1,848/5,747).
Statistical analysis. Association tests and meta-analysis.
A frequentist association test between genotypes and the binary phenotype was performed using SNPTEST under an additive genetic model. Ten principal components were included as covariates in the logistic regression model to control for population stratification, although genomic inflation was acceptable even before this correction was applied (unadjusted λ GC < 1.05). The λ GC value in the combined analysis following correction with principal components was 1.023 (1.012 and 1.022 for cohorts 1 and 2, respectively; Supplementary Fig. 1 ). Genotype uncertainty, generated by the calling algorithm or by imputation, was factored into the association test using the -method score option in SNPTEST. For markers on the X chromosome, the association test was performed assuming a standard model of complete X inactivation and an equal effect size in men and women, and providing sex information for each sample. In this model, male genotypes were encoded as 0/1 and female genotypes were coded as 0/0.5/1. Meta-analysis was performed using a fixed-effects model and default parameters in META 40 . Cluster plots for associated SNPs were visually inspected to verify genotype calls and, if imputed, were directly genotyped to confirm the result (TaqMan SNP Genotyping Assay; Supplementary Table 1) . Cross-conditioning analysis of the MHC region was performed in SNPTEST using the combined data set and including the lead HLA allele (HLA-B*08:01) as a covariate. Cross-conditioning analysis of HLA allelic associations was performed using logistic regression in the combined data set and including genotype at the lead SNP (rs9279411) as a covariate (Supplementary Table 3) .
Zero-inflated Poisson regression analysis.
To determine whether the results were influenced by differences in the length of follow-up in the poor-prognosis Crohn's disease subgroup, a zero-inflated Poisson regression model was fitted to the count data of total treatment escalations per patient (immunomodulators and surgery) using the 'zeroinfl' function in pscl in R (ref. 41) . This was confirmed to be the most appropriate model for the data using Vuong's closeness test (data not shown). Poisson regression was then performed, and disease duration was included within the regression terms to assess whether prognosis-associated SNPs were associated with treatment escalation rate independent of disease duration (Supplementary Table 5) .
Disease-associated SNP analysis. 170 Crohn's disease susceptibility loci were identified from a recent large meta-analysis 31 (Supplementary Table 10) .
Because several of these SNPs have been associated with specific anatomical distributions of Crohn's disease, which can confound assessments of disease course if there are differences in disease location between the prognostic subgroups 7, 10, 11, 16 , we stratified this analysis for disease location in addition to the top ten principal components. Disease location data were available for 88.2% of samples (n = 2,413; 779 good-prognosis cases, 1,634 poor-prognosis cases). Samples for whom disease location data were not available were excluded. To improve power to detect smaller effects, a candidate gene analysis was performed including only the 170 susceptibility variants and correcting for multiple testing using the Bonferroni method or false discovery rate (FDR q < 0.25). This analysis was predicted to have ≥80% power to detect variants (MAF > 20%) with odds ratios ≥1. 25 and should have been adequately powered to identify effects that were previously reported in unstratified analyses 42 . For this analysis, approximate Bayes factors were also calculated using the method described in ref. 43 . The prior variance was based on there being an equivalent effect size to that observed in a recent susceptibility meta-analysis 31 .
HLA allelic association analysis. The MHC region on chromosome 6 (chr. 6: 25,092,012-35,092,011) was extracted from the post-quality-control data set and used to impute 199 classical HLA alleles with HLA*IMP:02 (ref. 44) . Alleles imputed with confidence of >80% were retained for association testing. Imputed HLA alleles for both cohorts were combined into a single data set, and univariate logistic regression was performed without covariates.
Nominal P values were calculated from the Wald statistic 45 . The statistical significance threshold was adjusted using a Bonferroni correction for multiple testing. Reference allele frequency and haplotype data were obtained from the National Bone Marrow Donor Program (see URLs; Six-Locus High-Resolution HLA A~C~B~DRB3/4/5~DRB1~DQB1 Frequencies).
RNA expression analysis. Raw RNA sequencing data (fastq files) were downloaded from publically available repositories: GSE45326 (ref. 46) (Gene Expression Omnibus) and E-MTAB-513 (ArrayExpress). Reads were aligned to the UCSC RefSeq genes (hg19) using Star 47 and quantified, normalized, and analyzed using Cufflinks v2.
(ref. 48) (Seven Bridges Genomics platform; see URLs).
Pathway analysis. Two approaches were used for pathway analysis. In the SNPsea approach, pathways and cell types that are likely to be affected by prognosis-associated loci were identified using SNPsea 49 . In separate analyses, we assessed the enrichment of an LD-pruned list of 34 prognosis-associated SNPs (r 2 < 0.6, meta P < 1 × 10 −5 ) in 1,751 GO pathways and 155 primary human cell types and conditions (comprising 745 individual samples) 30 . Empirical P values were calculated by permutation using null SNP sets (matched for the number of linked genes) from a list of LD-pruned SNPs (subset of SNPs from the 1000 Genomes Project). Reference data including the null SNP sets, NCBI gene intervals, GO pathways, and SNP linkage intervals, were provided in SNPsea software.
In the DAPPLE approach, physical interactions between proteins encoded by genes at prognosis-associated loci were assessed using DAPPLE 50 , on the basis of a list of SNPs with meta P < 1 × 10 −4 .
Genetic risk scores. Weighted genetic risk scores were calculated using the PredictABEL package 51 with SNPs and their corresponding β coefficients as reported in Liu et al. 31 (for the 170 Crohn's disease GWAS hits; Fig. 4) or Wei et al. 33 (who generated a 573-SNP classifier from 10,799 SNPs with P < 1 × 10 −4 in a cohort of ~17,000 Crohn's disease cases and ~22,000 controls; Supplementary Fig. 8 ). Unweighted susceptibility allele counts were calculated by summing the number of risk alleles without including a β coefficient. Statistical significance was assessed using an unpaired two-tailed Student's t test. Data were stratified for disease location, and the results were combined using META 40 .
LD score regression. LD score regression 52 was performed using LD Hub 53 , a centralized database of summary-level GWAS results that provides a web interface for LD score regression. For this analysis, the MHC region was removed, as recommended by LD Hub (because its complex genetic architecture is not adequately captured by simple LD). Genetic correlation was then calculated between the prognosis meta-analysis results (stratified for disease location) and the summary statistics from the largest Crohn's disease susceptibility metaanalysis thus far 31 .
Data availability. Genotyping data that support the findings of this study have been deposited in the European Genome-phenome Archive (EGA) with the following accessions: EGAD00000000005 (cohort 1) and EGAS00001002147 (cohort 2). Summary statistics can also be downloaded from ftp://ftp.sanger. ac.uk/pub/project/humgen/summary_statistics/human/2016-10-12/CD_ prognosis_GWA_results.csv.zip.
